Mouse GM-CSF ELISpot Development Kit from R&D Systems
...t contains the basic components required for the d...nd recombinant rat Thymus Chemokine-1 in cell cult...ient materials to run ELISAs on approximately fift...nditions are met: The assay is run as summarized...
Custom Conjugation Services from SoluLink
Rabbit Anti-Blimp-1 (H-150) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products:(Date:11/24/2009)...Nov. 24 NeurogesX, Inc. ...sed on developing and commercializing novel pain m...DiTonno, President and Chief Executive Officer, is...fray Health Care Conference, to be held December 1... New York. ,, Mr. DiTonno and Stephen Ghiglier...
(Date:11/24/2009)...swire/ -- Blue Marble Energy Corp. announced today...t Authority (OPDA) were recently awarded $2 millio...ization Board (CERB) in a private/public partnersh...mical biorefinery in Lincoln County, WA. ,, "...opment of our biorefinery and bring over 70 green ...
(Date:11/24/2009)...endpoint has been met for patients with advanced-s...UEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEter...Company"), a global biopharmaceutical company focu...nced positive efficacy data from a Phase 2 study w...-108 (formerly AN-152), in patients with advanced ...
(Date:11/24/2009)...4 Shire plc (LSE: SHP,N...tical company, today,announced that it has submitt...glucerase alfa, the company,s enzyme replacement t...Gaucher disease. This is the third marketing,appli...ted, with previous,submissions in the United State...
Breaking Biology Technology:NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 4